ReviewClinical interventions in aging2008
Lubiprostone: a novel treatment for chronic constipation.
Review in Clinical interventions in aging, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04138004 (Comparison of Colon Preparation With 2-Litre Polyethylene Glycol), which is not on this map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Comparison of Colon Preparation With 2-Litre Polyethylene Glycol (PEG) Split-dose in Combination With Lubiprostone Versus 4-Litre Polyethylene Glycol (PEG) Split-dose: a Randomized Controlled Trial
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 80 citations in OpenAlex.
- Chronic constipation: A review of literature.Medicine · 2018Pooled it
- Lubiprostone in chronic kidney disease: Insights into mitochondrial function and polyamines from a randomized phase 2 clinical trial.Science advances · 2025Trial
- Lubiprostone Reduces Fat Content on MRI-PDFF in Patients With MASLD: A 48-Week Randomised Controlled Trial.Alimentary pharmacology & therapeutics · 2025Trial
- Bowel preparation using 2-L split-dose polyethylene glycol regimen plus lubiprostone versus 4-L split-dose polyethylene glycol regimen: a randomized controlled trial.BMC gastroenterology · 2022Trial
- Addition of Lubiprostone to polyethylene glycol(PEG) enhances the quality & efficacy of colonoscopy preparation: a randomized, double-blind, placebo controlled trial.BMC gastroenterology · 2016Trial
- Review
- Sex-specific transcriptome similarity networks elucidate comorbidity relationships.Communications medicine · 2025Article
- Comparative Effectiveness of Lubiprostone and Stool Softeners on Risk of Kidney Outcomes in Patients with CKD.Clinical journal of the American Society of Nephrology : CJASN · 2025Article
- Current Treatment Options for Children with Functional Constipation-What Is in the Pipeline?Children (Basel, Switzerland) · 2025Review
- Patient-Centered Approach in IBS-C Management.Gastroenterology & hepatology · 2025Article
- Raising Expectations in IBS-C Management.Gastroenterology & hepatology · 2025Article
- A Review of Pharmacologic and Non-Pharmacologic Therapies in the Management of Irritable Bowel Syndrome: Current Recommendations and Evidence.Journal of clinical medicine · 2024Review
- Lubiprostone Improves Distal Segment-Specific Colonic Contractions through TRPC4 Activation Stimulated by EP3 Prostanoid Receptor.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Leaky Gut Syndrome: Myths and Management.Gastroenterology & hepatology · 2024Article
- A Case Study in the IBS-C Management Continuum: Assessing Patient Response and Tailoring Treatment.Gastroenterology & hepatology · 2024Article
- Effectiveness and safety of lubiprostone after switching from stimulant laxatives in elderly patients with chronic constipation.JGH open : an open access journal of gastroenterology and hepatology · 2023Article
- Understanding the Current Approaches in the Management of IBS-C: A Case Study.Gastroenterology & hepatology · 2023Article
- Myths and misconceptions about childhood constipation.European journal of pediatrics · 2023Review
- Article
- Antipsychotic-Induced Constipation: A Review of the Pathogenesis, Clinical Diagnosis, and Treatment.CNS drugs · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic constipation is highly prevalent, reduces patients' quality of life, and imposes a significant health care burden on society. Lifestyle modifications and over-the-counter agents improve symptoms of constipation in some patients, however many patients have persistent symptoms and require the use of prescription medications. Three prescription medications are currently Food and Drug Administration (FDA) approved and available for the treatment of chronic constipation in adults. This review will focus on lubiprostone, the newest medication available for the treatment of chronic constipation. Lubiprostone is a bicyclic fatty acid metabolite analogue ofprostaglandin E1. It activates specific chloride channels in the gastrointestinal tract to stimulate intestinal fluid secretion, increase gastrointestinal transit, and improve symptoms of constipation. This article will provide a brief overview on chloride channel function in the gastrointestinal tract, describe the structure, function, and pharmacokinetics of lubiprostone, and discuss the safety and efficacy of this new medication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.